NCT07026279View on ClinicalTrials.gov

A Study of Narmafotinib Given in Combination With Modified FOLFIRINOX in Patients With Metastatic Pancreatic Cancer

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

August 18, 2025

Primary Completion Date

July 31, 2029

Study Completion Date

July 31, 2029

Conditions
Pancreatic Cancer Metastatic
Interventions
DRUG

narmafotinib ascending doses

once daily capsules

DRUG

narmafotinib dose comparison

once daily capsules

Trial Locations (2)

2065

RECRUITING

GenesisCare, St Leonards

3121

RECRUITING

Epworth Healthcare, Richmond

Sponsors
All Listed Sponsors
lead

Amplia Therapeutics Limited

INDUSTRY

NCT07026279 - A Study of Narmafotinib Given in Combination With Modified FOLFIRINOX in Patients With Metastatic Pancreatic Cancer | Biotech Hunter | Biotech Hunter